Shire plc (ADR) (NASDAQ:SHPG)

Stifel Has 5 Specialty Pharmaceutical 2018 Buys With Massive Upside Potential

Despite a roaring market in 2017, in which the S&P 500 was up almost 20% on the year, the specialty pharmaceutical group and biotechs severely underperformed. In addition, the performance ...
Read Full Story »

What Shire Is Planning With Its Newest FDA Submission

Although Shire PLC (NASDAQ: SHPG) is not seeing much of a bump in its share price, the firm is creating a lot of value with its most recent submission to ...
Read Full Story »

4 Large Cap Pharmaceutical Stocks That Could Post Big Earnings

With a market that has become as expensive as this one, there is one key driver that can keep things going, and that’s positive earnings or guidance for the next ...
Read Full Story »

10 Credit Suisse Top European Stock Picks for US Investors

The U.S. stock market is currently sitting at all-time highs, and investors have to keep in mind that this bull market is now nearly nine years old. For about five ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Apple, Chesapeake Energy, DowDuPont, Equifax, Gap, Nike, Tesla, Under Armour and More

Stocks were indicated to open marginally higher on Tuesday, but investors need to keep in mind that the major equity indexes are at or just under all-time highs. Investors keep ...
Read Full Story »

Leon Cooperman Sees Mixed Market Ahead but Loves 5 Top Stock Picks

Leon Cooperman of Omega Advisors spoke at the Delivering Alpha conference on Tuesday morning. He is a heavyweight on Wall Street and is considered one of the preeminent hedge fund ...
Read Full Story »

SunTrust Says Big Pharmaceuticals Have Multiple Catalysts for the Rest of 2017

Healthcare, which struggled mightily during the brutal election season last year and even back into 2015, has had a nice first half of 2017. Given the current nosebleed levels of ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Costco, Deckers Outdoor, Qualcomm, Shell, Shire, Ulta Beauty and More

The market continued its winning ways yesterday, and while we're off to a slow start this morning, it’s looking like the month of May should end up closing out with gains ...
Read Full Story »

Merrill Lynch Raises Price Targets on 5 Stocks With Blow-Out Earnings

The higher the market goes, the harder it is to justify many of the multiples being applied to shares. The big moves in the market since the election last November ...
Read Full Story »
Medicine pills

Top Analyst Thinks Big Pharmaceutical Stocks Will Outperform the Rest of 2016

Ever since the Hillary Clinton high drug price tweet in September of last year, the major pharmaceuticals and biotechs have struggled, and while performance has improved over the past quarter, ...
Read Full Story »
blue eye

Shire Gains Key FDA Approval in Dry Eye Treatment

Shire PLC (NASDAQ: SHPG) made waves Tuesday morning following a key U.S. Food and Drug Administration (FDA) approval. The company announced that the FDA has approved Xiidra (lifitegrast ophthalmic solution) 5%, ...
Read Full Story »
Pills and tablets

Pfizer and Shire Move on IBD License Agreement

Pfizer Inc. (NYSE: PFE) made waves early on Tuesday after the announcement of its newest licensing deal. Shire PLC (NASDAQ: SHPG) announced it has agreed to license global rights to all indications ...
Read Full Story »
buy now

4 Top Jefferies Value Stocks to Buy With Big Upside Potential

Despite last Friday's meager payroll gains, most of Wall Street seems to be taking the low number as an anomaly and looking at overall brighter economic news. That was the case as ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Alibaba, ADM, CSC, Infosys, Microsoft, Wells Fargo, WisdomTree and More

Stocks were indicated higher on Thursday, after gains on Tuesday and Wednesday were handy. Oil also crossed back above the $50 barrier again for the first time since October 2015. ...
Read Full Story »
white pills

Biotech and Pharmaceuticals Highlight Jefferies Top Growth Stock Buys

With earnings season hitting its stride this week, many investors are looking to see how the companies they own perform. Two areas that have lagged all year long are biotech ...
Read Full Story »